pharmaphorum
MARCH 19, 2021
The pandemic has ushered in a number of major changes to healthcare systems, notably in the ways in which pharmaceutical companies communicate, visit and engage with physicians. Florent Edouard is the global head of commercial excellence at Grünenthal Group , a pharmaceutical company headquartered in Germany and specialised in pain.
European Pharmaceutical Review
JULY 7, 2022
Dr Eric Hughes joins Teva with experience in all phases of drug development at global pharmaceutical companies, most recently Boston-based Vertex Pharmaceuticals, which he joined last year. He will be based out of Teva’s US headquarters in Parsippany, New Jersey. . Dr Hughes earned his MD and PhD at Yale School of Medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
APRIL 8, 2024
A study investigating the trend for existing pharmaceutical companies to outsource to contracted development and manufacturing organisations (CDMOs), analysing the position of companies manufacturing monoclonal antibody drugs (mAbs). Yoshiura et al. Yoshiura et al.
Pharmaceutical Technology
MAY 17, 2023
Swiss pharmaceutical company IDEOGEN will be responsible for commercialising Glassia in the country. To ensure wide access to eligible patients, we are excited to partner with the IDEOGEN Group, a company focused on the commercialisation of speciality medicines for rare diseases across Europe.”
Pharmaceutical Technology
JUNE 29, 2022
A drug can also be considered for an orphan drug designation if a pharmaceutical company is unlikely to reclaim the research, development, and approval costs in addition to reasonable profit for a drug within seven years of an FDA approval.
Pharmaceutical Technology
MAY 8, 2023
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.
pharmaphorum
APRIL 11, 2022
In 2010, when we founded VivoSense, we developed a software platform for analysis of wearable sensor data and electronic patient-recorded outcomes (PRO) and patient diary information. If pharmaceutical companies do not use this data, someone else will. How can this data be incorporated into clinical trials?”. Tabakin agrees. “In
Expert insights. Personalized for you.
141 
Let's personalize your content